AP2011005943A0 - Atropisomers of 2-purinyl-3-tolylquinazolinone derivatives and methods of use. - Google Patents

Atropisomers of 2-purinyl-3-tolylquinazolinone derivatives and methods of use.

Info

Publication number
AP2011005943A0
AP2011005943A0 AP2011005943A AP2011005943A AP2011005943A0 AP 2011005943 A0 AP2011005943 A0 AP 2011005943A0 AP 2011005943 A AP2011005943 A AP 2011005943A AP 2011005943 A AP2011005943 A AP 2011005943A AP 2011005943 A0 AP2011005943 A0 AP 2011005943A0
Authority
AP
ARIPO
Prior art keywords
tolylquinazolinone
atropisomers
purinyl
derivatives
methods
Prior art date
Application number
AP2011005943A
Other languages
English (en)
Inventor
Jerry B Evarts
Roger G Ulrich
Original Assignee
Gilead Calistoga Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42289320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2011005943(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Calistoga Llc filed Critical Gilead Calistoga Llc
Publication of AP2011005943A0 publication Critical patent/AP2011005943A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AP2011005943A 2009-03-24 2010-03-24 Atropisomers of 2-purinyl-3-tolylquinazolinone derivatives and methods of use. AP2011005943A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16298009P 2009-03-24 2009-03-24
US23155009P 2009-08-05 2009-08-05
PCT/US2010/028554 WO2010111432A1 (en) 2009-03-24 2010-03-24 Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use

Publications (1)

Publication Number Publication Date
AP2011005943A0 true AP2011005943A0 (en) 2011-10-31

Family

ID=42289320

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011005943A AP2011005943A0 (en) 2009-03-24 2010-03-24 Atropisomers of 2-purinyl-3-tolylquinazolinone derivatives and methods of use.

Country Status (19)

Country Link
US (1) US8440677B2 (ko)
EP (1) EP2411391A1 (ko)
JP (1) JP2012521994A (ko)
KR (1) KR20120002995A (ko)
CN (1) CN102439012A (ko)
AP (1) AP2011005943A0 (ko)
AU (1) AU2010229968A1 (ko)
BR (1) BRPI1012333A2 (ko)
CA (1) CA2756347A1 (ko)
CL (1) CL2011002359A1 (ko)
CO (1) CO6450655A2 (ko)
EA (1) EA019499B1 (ko)
EC (1) ECSP11011412A (ko)
IL (1) IL215251A0 (ko)
MX (1) MX2011009955A (ko)
NZ (1) NZ595307A (ko)
PE (1) PE20120602A1 (ko)
SG (1) SG174529A1 (ko)
WO (1) WO2010111432A1 (ko)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
WO2005016348A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
KR20170060179A (ko) 2008-11-13 2017-05-31 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
KR20120002995A (ko) 2009-03-24 2012-01-09 길리아드 칼리스토가 엘엘씨 ２―퓨리닐―３―톨릴―퀴나졸리논 유도체의 회전장애 이성질체 및 사용 방법
SG175259A1 (en) * 2009-04-20 2011-11-28 Gilead Calistoga Llc Methods of treatment for solid tumors
WO2010138577A1 (en) * 2009-05-29 2010-12-02 Merck Sharp & Dohme Corp. Radiolabeled pde10 inhibitors
KR20120049281A (ko) * 2009-07-21 2012-05-16 길리아드 칼리스토가 엘엘씨 Ｐｉ３ｋ 억제제를 이용한 간 장애의 치료
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
EP2518070A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
EP2518071A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EA029473B1 (ru) 2011-12-15 2018-03-30 Новартис Аг Применение ингибиторов pi3k для лечения острой и церебральной малярии
KR20140133590A (ko) 2012-03-05 2014-11-19 길리아드 칼리스토가 엘엘씨 (s)-2-(1-(9h-퓨린-6-일아미노)프로필)-5-플루오로-3-페닐퀴나졸린-4(3h)-온의 다형체 형태
SI2834244T1 (sl) 2012-03-13 2016-12-30 Respivert Limited Inhibitorji kristalinične PI3 kinaze
KR102216606B1 (ko) 2012-07-04 2021-02-17 리젠 파마슈티컬스 소시에떼 아노님 선택적 pi3k 델타 억제제
WO2014015523A1 (en) * 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
GEP201706623B (en) * 2012-10-16 2017-02-10 Almirall Sa Pyrrolotriazinone derivatives as pi3k inhibitors
WO2014060431A1 (en) * 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
JP6434416B2 (ja) 2012-11-08 2018-12-05 ライゼン・ファーマシューティカルズ・エスアー ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物
AR095353A1 (es) 2013-03-15 2015-10-07 Respivert Ltd Compuesto
JO3279B1 (ar) * 2013-03-15 2018-09-16 Respivert Ltd مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
CN104513235B (zh) * 2013-09-02 2017-12-05 广东东阳光药业有限公司 取代的氨基嘧啶类化合物及其使用方法和用途
SG11201600028YA (en) * 2013-09-22 2016-02-26 Calitor Sciences Llc Substituted aminopyrimidine compounds and methods of use
EP3594215A1 (en) 2013-12-20 2020-01-15 Gilead Calistoga LLC Intermediate products in process methods for the preparation of phosphatidylinositol 3-kinase inhibitors
EP3083623A1 (en) 2013-12-20 2016-10-26 Gilead Calistoga LLC Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
ES2880999T3 (es) 2014-05-27 2021-11-26 Rhizen Pharmaceuticals S A Sal de tosilato cristalina de un inhibidor selectivo de PI3K delta para uso en formulaciones farmacéuticas
US20170158699A1 (en) * 2014-05-27 2017-06-08 Almirall, S.A. Addition salts of (s)-2-(1-(6-amino-5-cyanopyrimidin-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1,2,4]triazine-5-carbonitrile
EP3154960A1 (en) 2014-06-13 2017-04-19 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
CN106470996B (zh) 2014-07-04 2019-02-22 鲁平有限公司 作为pi3k抑制剂的喹嗪酮衍生物
WO2017027883A1 (en) 2015-08-13 2017-02-16 San Diego State University Research Foundation Atropisomerism for increased kinase inhibitor selectivity
US11351209B2 (en) 2016-01-11 2022-06-07 Queen Mary University Of London Inhibitors of PI3K p-delta 110 for use in delivery of viruses in the treatment of cancer
CN109641887B (zh) 2016-06-22 2022-09-20 美国政府健康及人类服务部 可用作用于治疗癌症的突变idh1抑制剂的噻唑衍生物
US10016425B2 (en) 2016-11-03 2018-07-10 King Saud University Anti-ulcerative colitis compound
WO2020038394A1 (zh) * 2018-08-21 2020-02-27 南京明德新药研发有限公司 吡唑并嘧啶衍生物及其作为pi3k抑制剂的应用
AU2021253584A1 (en) 2020-04-10 2022-11-17 Gb005, Inc. Kinase inhibitors

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1053063A (ko) 1963-05-18
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
DE2027645A1 (de) 1970-06-05 1971-12-09 Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
NL7204972A (ko) 1971-04-21 1972-10-24
US3897432A (en) 1971-04-21 1975-07-29 Merck & Co Inc Substituted benzimidazole derivatives
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
DE2644265C2 (de) 1976-09-30 1983-02-10 Bayer Ag, 5090 Leverkusen Chinazoline
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4183931A (en) 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
DE2812635A1 (de) 1978-03-22 1979-09-27 Bayer Ag Heterocyclische verbindungen
JPS55118918A (en) 1979-03-06 1980-09-12 Mitsubishi Electric Corp Production of quinazolone ring-containing epoxy resin
JPS55118917A (en) 1979-03-06 1980-09-12 Mitsubishi Electric Corp Production of quinazolone ring-containing epoxy resin
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
JPS6017375B2 (ja) 1979-06-20 1985-05-02 三菱電機株式会社 ポリアミド樹脂の製造方法
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
USRE35862E (en) 1986-08-18 1998-07-28 Emisphere Technologies, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US6696250B1 (en) 1986-12-03 2004-02-24 Competitive Technologies, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
EP0364598A4 (en) 1988-03-02 1992-01-15 Yoshitomi Pharmaceutical Industries, Ltd. 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof
US5225347A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
FR2675803B1 (fr) 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
DK0525960T3 (da) 1991-06-18 1996-04-15 American Home Prod Anvendelse af rapamycin til behandling af T-celle leukæmi/lymfon
JPH07505915A (ja) 1992-04-14 1995-06-29 コーネル　リサーチ　ファウンデーション、インコーポレーテッド 樹枝状巨大分子およびその製造法
US5658780A (en) 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US5378725A (en) 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
FI951367A (fi) 1994-03-28 1995-09-29 Japan Energy Corp Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
US5480906A (en) 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
RU2203669C2 (ru) 1994-08-12 2003-05-10 Про-Нейрон Инк. Способы лечения сепсиса и воспалений с помощью оксипуриновых нуклеозидов
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
JP3233802B2 (ja) 1994-12-15 2001-12-04 関西電力株式会社 燃焼排ガス中の炭酸ガスと窒素酸化物を除去する方法
US6043062A (en) 1995-02-17 2000-03-28 The Regents Of The University Of California Constitutively active phosphatidylinositol 3-kinase and uses thereof
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5948664A (en) 1996-02-29 1999-09-07 The Regents Of The University Of California PI 3-kinase polypeptides
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP0901487B9 (en) 1996-05-15 2004-09-29 Pfizer Inc. 2,3,6 trisubstituted-4(3h)-quinazolinones
GB9611460D0 (en) 1996-06-01 1996-08-07 Ludwig Inst Cancer Res Novel lipid kinase
US5858753A (en) 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
PT958296E (pt) 1996-12-31 2003-11-28 Reddys Lab Ltd Dr Compostos heterociclicos processo para a sua preparacao composicoes farmaceuticas contendo-os e sua utilizacao no tratamento da diabetes e doencas relacionadas
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
JP2000509731A (ja) 1997-02-28 2000-08-02 ファイザー・プロダクツ・インク ３−アリール−４（３ｈ）−キナゾリノンのアトロプ異性体およびａｍｐａ受容体アンタゴニストとしてのそれらの使用
EA001961B1 (ru) 1997-02-28 2001-10-22 Пфайзер Продактс Инк. Атропизомеры 3-гетероарил-4(3н)-хиназолинонов для лечения нейродегенеративных и связанных с травмами цнс состояний
DE69831446T2 (de) 1997-06-09 2006-06-14 Pfizer Prod Inc Chinazolin-4-on AMPA Antagonisten
WO1999001139A1 (en) 1997-07-03 1999-01-14 Thomas Jefferson University An improved method for design and selection of efficacious antisense oligonucleotides
IL125950A0 (en) 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
AU2108299A (en) 1998-01-08 1999-07-26 University Of Virginia Patent Foundation A2A adenosine receptor agonists
CN1208326C (zh) 1998-04-23 2005-06-29 雷迪实验室有限公司 杂环化合物及其在医药方面的应用、其制备方法及含有它们的药物组合物
US6048970A (en) 1998-05-22 2000-04-11 Incyte Pharmaceuticals, Inc. Prostate growth-associated membrane proteins
US6100090A (en) 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
US6046049A (en) 1999-07-19 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of PI3 kinase p110 delta expression
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP1939203B1 (en) 2000-04-25 2014-11-19 ICOS Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform
EP1278748B1 (en) * 2000-04-25 2011-03-23 ICOS Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
AU2003255528B2 (en) 2002-07-10 2009-07-16 Merck Serono Sa Azolidinone-vinyl fused-benzene derivatives
US20040092561A1 (en) 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
GB0217777D0 (en) 2002-07-31 2002-09-11 Novartis Ag Organic compounds
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
CA2400254A1 (en) 2002-09-19 2004-03-19 University Health Network Compositions and methods for treating heart disease
UA82205C2 (en) 2002-09-30 2008-03-25 Байер Фармасьютикалз Корпорейшн Fused azole-pyrimidine derivatives
EP1569653A1 (en) 2002-12-06 2005-09-07 Warner-Lambert Company LLC Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k
CA2510851A1 (en) 2002-12-20 2004-07-08 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
WO2004089925A1 (en) 2003-04-03 2004-10-21 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
WO2004108708A1 (en) 2003-06-05 2004-12-16 Warner-Lambert Company Llc 3-substituted indoles and derivatives thereof as therapeutic agents
US20040259926A1 (en) 2003-06-05 2004-12-23 Bruendl Michelle M. 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
EP1644364A1 (en) 2003-06-05 2006-04-12 Warner-Lambert Company LLC Tetrazol benzofurancarboxamides with pi3k activity as therapeutic agents
MXPA05012953A (es) 2003-06-05 2006-02-13 Warner Lambert Co Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos.
EP1636212B1 (en) 2003-06-05 2007-06-27 Warner-Lambert Company LLC Cycloalkylsulfanyl substituted benzo¬b|thiophenes as therapeutic agents
BRPI0410913A (pt) 2003-06-05 2006-06-27 Warner Lambert Co benzotiofenos substituìdos com cicloalquil e heterocicloalquil como agentes terapêuticos
WO2005016349A1 (en) 2003-08-14 2005-02-24 Icos Corporation Methods of inhibiting leukocyte accumulation
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
WO2005067901A2 (en) 2004-01-08 2005-07-28 Michigan State University Methods for treating and preventing hypertension and hypertension-related disorders
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
CA2566436C (en) 2004-05-13 2011-05-10 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
CA2567883A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
JP2008501707A (ja) * 2004-06-04 2008-01-24 アイコス、コーポレーション マスト細胞障害を処置するための方法
CA2598409A1 (en) 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
TW200811185A (en) 2005-12-22 2008-03-01 Prolexys Pharmaceuticals Inc Fused pyrimidones and thiopyrimidones, and uses thereof
JP5313909B2 (ja) 2006-11-13 2013-10-09 アイコス コーポレイション 炎症性疾患および癌の処置のためのチエノピリミジノン
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
WO2009058361A1 (en) 2007-10-31 2009-05-07 Dynavax Technologies Corp. Inhibition of type i ifn production
JP5869222B2 (ja) 2008-01-04 2016-02-24 インテリカイン， エルエルシー 特定の化学的実体、組成物および方法
KR20170060179A (ko) 2008-11-13 2017-05-31 길리아드 칼리스토가 엘엘씨 혈액 종양에 대한 요법
CA2745280A1 (en) 2008-12-04 2010-06-10 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
KR20120002995A (ko) 2009-03-24 2012-01-09 길리아드 칼리스토가 엘엘씨 ２―퓨리닐―３―톨릴―퀴나졸리논 유도체의 회전장애 이성질체 및 사용 방법
SG175259A1 (en) 2009-04-20 2011-11-28 Gilead Calistoga Llc Methods of treatment for solid tumors
KR20120049281A (ko) * 2009-07-21 2012-05-16 길리아드 칼리스토가 엘엘씨 Ｐｉ３ｋ 억제제를 이용한 간 장애의 치료
MX2020004501A (es) 2010-06-03 2021-11-09 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).

Also Published As

Publication number Publication date
CA2756347A1 (en) 2010-09-30
NZ595307A (en) 2013-11-29
BRPI1012333A2 (pt) 2016-03-29
EA201171160A1 (ru) 2012-04-30
JP2012521994A (ja) 2012-09-20
AU2010229968A1 (en) 2011-10-13
KR20120002995A (ko) 2012-01-09
CN102439012A (zh) 2012-05-02
US8440677B2 (en) 2013-05-14
CL2011002359A1 (es) 2012-04-09
MX2011009955A (es) 2011-11-18
IL215251A0 (en) 2011-12-29
PE20120602A1 (es) 2012-05-21
SG174529A1 (en) 2011-10-28
ECSP11011412A (es) 2012-03-30
CO6450655A2 (es) 2012-05-31
EP2411391A1 (en) 2012-02-01
WO2010111432A1 (en) 2010-09-30
EA019499B1 (ru) 2014-04-30
US20100249155A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
AP2011005943A0 (en) Atropisomers of 2-purinyl-3-tolylquinazolinone derivatives and methods of use.
HK1194071A1 (en) Certain triazolopyrazines, compositions thereof and methods of use therefor
IL236830A0 (en) Diazahomoredene derivatives and methods of using them
HK1164050A1 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
EP2367866A4 (en) POLYESTER, MANUFACTURING METHOD THEREFOR AND USE
ZA201109034B (en) Aminopyrrolidinone derivatives and uses thereof
IL213974A0 (en) Isoxazole-isoxazole and isoxazole-isothiazole derivatives
HK1149933A1 (en) Diazacarbazoles and methods of use
EP2561072A4 (en) NANOZYMES, PROCESSES FOR PRODUCING NANOZYMES, AND METHODS OF USING NANOZYMES
IL209548A0 (en) Diazacarbazoles and methods of use
IL214500A0 (en) Compositions and methods for extended therapy with aminopyridines
IL219888A0 (en) Pyridine-pyridinone derivatives, preparation and therapeutic use thereof
ZA201203025B (en) Connector, and methods of use
EP2393836A4 (en) SAM-6 VARIANTS, TARGET AND USE PROCESS
HK1173339A1 (en) Spirolactam derivatives and uses of same
EP2490541A4 (en) 2-SUBSTITUTED ETHYL HYLTHIAZONE DERIVATIVES AND THEIR USE
GB201211237D0 (en) CDK5 inhibitors and therapeutic uses thereof
IL214408A0 (en) Derivatives of 6-(6-substituted-triazolopyidazine-sulfanyl) 5-fluoro-benzothiazoles and 5-fluoro-benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors
GB2488494B (en) Solution, use and method of preparation thereof
HK1164861A1 (en) Substituted 3-benzofuranyl-indol-2-one-3-acetamidopiperazine derivatives, preparation thereof, and therapeutic use thereof
IL219935A0 (en) Small pyrimidine derivatives and methods of use thereof
EP2350212A4 (en) POLYAMINO-ACETONITRILES, PROCESSES FOR PREPARING THEM AND USE THEREOF
SI2421864T1 (sl) 1-pirazolo(4,3-c)izokinolinski derivati, njihova priprava in njihova terapevtska uporaba
EP2621490A4 (en) PROPARGYL-TRIFLUOROMETHOXY-AMINO-BENZOTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF
HK1174620A1 (zh) 吲唑基取代的二氫異噁唑並吡啶及其使用方法